B

Biocytogen Pharmaceuticals Beijing Co Ltd
HKEX:2315

Watchlist Manager
Biocytogen Pharmaceuticals Beijing Co Ltd
HKEX:2315
Watchlist
Price: 14.9 HKD -0.67% Market Closed
Market Cap: 6B HKD
Biocytogen Pharmaceuticals Beijing Co Ltd
/
Income Statement
/
Revenue

Biocytogen Pharmaceuticals Beijing Co Ltd
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Biocytogen Pharmaceuticals Beijing Co Ltd
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
B
Biocytogen Pharmaceuticals Beijing Co Ltd
HKEX:2315
Revenue
¥980.5m
CAGR 3-Years
40%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Revenue
¥17.4B
CAGR 3-Years
102%
CAGR 5-Years
68%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Revenue
¥9.4B
CAGR 3-Years
30%
CAGR 5-Years
55%
CAGR 10-Years
N/A
Akeso Inc
HKEX:9926
Revenue
¥4.5B
CAGR 3-Years
N/A
CAGR 5-Years
337%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Revenue
¥5.5B
CAGR 3-Years
33%
CAGR 5-Years
41%
CAGR 10-Years
N/A
S
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
Revenue
¥1.9B
CAGR 3-Years
291%
CAGR 5-Years
N/A
CAGR 10-Years
N/A

Biocytogen Pharmaceuticals Beijing Co Ltd
Glance View

Market Cap
6B HKD
Industry
Biotechnology

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. manufactures biological products and provides related biological services. The company is headquartered in Beijing, Beijing. The company went IPO on 2022-09-01. The firm operates two business segments. The Drug Development Business segment is mainly engaged in the research and development of oncology and autoimmune disease treatments, as well as antibody development. The Preclinical Research Service segment is mainly engaged in gene editing, preclinical pharmacological efficacy evaluation and model animal sales.

Intrinsic Value
9.41 HKD
Overvaluation 37%
Intrinsic Value
Price
B
What is Intrinsic Value?

See Also

What is Biocytogen Pharmaceuticals Beijing Co Ltd's Revenue?
Revenue
980.5m CNY

Based on the financial report for Dec 31, 2024, Biocytogen Pharmaceuticals Beijing Co Ltd's Revenue amounts to 980.5m CNY.

What is Biocytogen Pharmaceuticals Beijing Co Ltd's Revenue growth rate?
Revenue CAGR 3Y
40%

Over the last year, the Revenue growth was 37%. The average annual Revenue growth rates for Biocytogen Pharmaceuticals Beijing Co Ltd have been 40% over the past three years .

Back to Top
ALPHA SPREAD
Follow us
Join more than 242,800+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.